SCHEMBL12844634

SCHEMBL12844634

CCCc1ccnn1CCC

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C2 P08235 1/20 0.35
SLC9A1 P19634 1/20 0.35
MAPK1 P28482 1/20 0.34
ADRA1A P35348 1/20 0.33
ADORA2A P29274 1/20 0.32
ADORA2B P29275 1/20 0.32
DRD2 P14416 3/20 0.32
DRD4 P21917 3/20 0.32
DRD3 P35462 3/20 0.32
ALDH1A1 P00352 2/20 0.32
POLB P06746 1/20 0.32
GRM2 Q14416 1/20 0.32
KDM5A P29375 1/20 0.31
KDM5B Q9UGL1 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP19A1 P11511 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13500287 0.88 SLC9A1 (0.39) SLC9A1MAPK1ALDH1A1POLBGRM2
SCHEMBL12327546 0.85 NR3C2 (0.36) NR3C2SLC9A1MAPK1ADRA1AADORA2A
SCHEMBL4327171 0.82 NR3C2 (0.38) NR3C2SLC9A1MAPK1ADRA1AADORA2A
SCHEMBL9455595 0.82 NR3C2 (0.35) NR3C2SLC9A1MAPK1ADRA1AADORA2A
SCHEMBL16815383 0.82 NR3C2 (0.38) NR3C2SLC9A1MAPK1ADRA1AADORA2A
SCHEMBL21338111 0.82 KDM5A (0.31) MAPK1KDM5AKDM5B
SCHEMBL20661486 0.79
SCHEMBL861630 0.79 SLC9A1 (0.40) SLC9A1ALDH1A1KDM5AKDM5BCYP1A2
SCHEMBL12776230 0.79 MAPK1 (0.35) NR3C2SLC9A1MAPK1ADRA1AADORA2A
SCHEMBL20170905 0.79 ADRA1A (0.39) NR3C2SLC9A1MAPK1ADRA1AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902373-B2 asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide PFIZER INC (US) 2011-03-08 US disclosed
US-20080146569-A1 Nicotinamide Derivatives PFIZER INC. 2008-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146569-A1 Nicotinamide Derivatives NNT, NAMPT, NADK NR3C2 1201/4885SLC9A1 618/4885MAPK1 1305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.